A phase IIa trial has demonstrated that a structural analogue of warfarin is safe, tolerable, and efficacious. Investigators believe that this new anticoagulant, named tecarfarin, will be ...

Key barriers in adhering to anticoagulation guidelines included uncertainty about its choice, established practices, and the momentum of treatment once initiated.

Purpose: The chemistry, pharmacology, pharmacokinetics ... Conclusion: Ximelagatran has shown promise as a possible alternative to warfarin and other anticoagulants but will require further ...